자궁내막증에서 aromatase의 발현과 임상적 중등도와의 연관성
Expression of aromatase in endometiosis and its relation to clinical laboratory and surgical parameters
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Aromatase is the key enzyme for the conversion of C19 steroids into estrogen in certain human tissues. We studied to evaluate the aromatase expression in eutopic endometirum and endometriotic lesion and its relationship to clinical and laboratory parameters. Methods: The study included 78 cases of endometriotic lesion and 14 cases of eutopic endometrium and 30 cases of normal uterine endometrium obtained through laparoscopic surgery and curettage. The frozen tissue specimens were examined by immunohistochemistry using aromatase. Clinical symptoms, laboratory findings, and operative findings were analyzed and compared in according to aromatase expression. Results: We observed positive immunohistochemical expression for aromatase in endometriotic lesion from 46/78 patients (59.0%). Aromatase expression was elevated in comparison to eutopic endometrium (5/14 patients, P=0.032) and the difference was more pronounced when eutopic endometriums from patients with endometriosis were compared with those of healthy controls (2/30 patients, P<0.001). Aromatase-positive patients had more moderate-to-severe chronic pelvic pain, higher CA-125 level significantly. Also in operative findings,severe grade endometriosis, bilateral endometriomas, and associated leiomyoma and adenomyosis were more frequent in aromatase positive patients. High values of white blood cell count, erythrocyte sedimentation rate, CA 19-9 were more frequent in aromatase positive patients notwithstanding insignificant differences. Conclusion: Unopposed local biosynthesis of estrogens by increased expression of aromatase in eutopic endometrium and endometrial tissue could be involved in the development or maintenance of endometriosis and other uterine estrogen-triggered diseases. Our findings suggest increased expression of aromatase may be related with severity, activity, and chronic pelvic pain in patients with endometriosis
Abstract
Objective: Aromatase is the key enzyme for the conversion of C19 steroids into estrogen in certain human tissues. We studied to evaluate the aromatase expression in eutopic endometirum and endometriotic lesion and its relationship to clinical and laboratory parameters. Methods: The study included 78 cases of endometriotic lesion and 14 cases of eutopic endometrium and 30 cases of normal uterine endometrium obtained through laparoscopic surgery and curettage. The frozen tissue specimens were examined by immunohistochemistry using aromatase. Clinical symptoms, laboratory findings, and operative findings were analyzed and compared in according to aromatase expression. Results: We observed positive immunohistochemical expression for aromatase in endometriotic lesion from 46/78 patients (59.0%). Aromatase expression was elevated in comparison to eutopic endometrium (5/14 patients, P=0.032) and the difference was more pronounced when eutopic endometriums from patients with endometriosis were compared with those of healthy controls (2/30 patients, P<0.001). Aromatase-positive patients had more moderate-to-severe chronic pelvic pain, higher CA-125 level significantly. Also in operative findings,severe grade endometriosis, bilateral endometriomas, and associated leiomyoma and adenomyosis were more frequent in aromatase positive patients. High values of white blood cell count, erythrocyte sedimentation rate, CA 19-9 were more frequent in aromatase positive patients notwithstanding insignificant differences. Conclusion: Unopposed local biosynthesis of estrogens by increased expression of aromatase in eutopic endometrium and endometrial tissue could be involved in the development or maintenance of endometriosis and other uterine estrogen-triggered diseases. Our findings suggest increased expression of aromatase may be related with severity, activity, and chronic pelvic pain in patients with endometriosis
참고문헌 (26)
- Lebovic DI, "Immunobiology of endometriosis", Fertil Steril, 75, pp.1~10 (2001)
- Kitawaki J, "Endometriosis: the pathophysiology as an estrogen-dependent disease", J Steroid Biochem Mol Biol, 83, pp.149~155 (2002)
- Iwabe T, "Role of cytokines in endometriosis-associated infertility", Gynecol Obstet Invest, 53(1), pp.19~25 (2002)
- Gómez-Torres MJ, "Embryotoxicity of peritoneal fluid in women with endometriosis. Its relation with cytokines and lymphocyte populations", Hum Reprod, 17, pp.777~781 (2002)
- Matsuzaki S, "Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection", Fertil Steril, 85, pp.308~313 (2006)
- Dheenadayalu K, "Aromatase P450 messenger RNA expression in eutopic endometrium is not a specific marker for pelvic endometriosis", Fertil Steril, 78, pp.825~829 (2002)
- Noble LS, "Prostaglandin E2 stimulates aromatase expression in endometriosis- derived stromal cells", J Clin Endocrinol Metab, 82, pp.600~606 (1997)
- Bulun SE, "Endocrine disorders associated with inappropriately high aromatase expression", J Steroid Biochem Mol Biol, 61, pp.133~139 (1997)
- Ebert AD, "Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions-old answers?", Eur J Obstet Gynecol Reprod Biol, 122, pp.144~150 (2005)
- Attar E, "Aromatase and other steroidogenic genes in endometriosis: translational aspects", Hum Reprod Update, 12, pp.49~56 (2006)
- Acién P, "GnRH analogues, transvaginal ultrasound- guided drainage and intracystic injection of recombinant interleukin-2 in the treatment of endometriosis", Gynecol Obstet Invest, 55, pp.96~104 (2003)
- "Revised American Fertility Society classification of endometriosis: 1985", Fertil Steril, 43, pp.351~352 (1985)
- "Revised American Society for Reproductive Medicine classification of endometriosis: 1996", Fertil Steril, 67, pp.817~821 (1997)
- Velasco I, "Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis", Mol Hum Reprod, 12, pp.377~381 (2006)
- Bulun SE, "Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture", J Clin Endocrinol Metab, pp.736~743 (1994)
- Mousa NA, "Aromatase inhibitors in the treatment of severe endometriosis", Obstet Gynecol, 109, pp.1421~1423 (2007)
- Bulun SE, "Molecular basis for treating endometriosis with aromatase inhibitors", Hum Reprod Update, 6, pp.413~418 (2000)
- Maia H Jr, "Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use", Gynecol Endocrinol, 23, pp.320~324 (2007)
- Berstein LM, "Tumor estrogen content and clinico- morphological and endocrine features of endometrial cancer", J Cancer Res Clin Oncol, 129, pp.`249~ (2003)
- Acién P, "Miomas y reproducción. In Reproducción humana. 2nd ed", pp.245~262 (2002), McGraw-Hill Interamericana
- Bulun SE, "Aromatase in endometriosis and uterine leiomyomata", J Steroid Biochem Mol Biol, 95, pp.57~62 (2005)
- Heilier JF, "Expression of aromatase (P450 aromatase", CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum, 2006, pp.85, 1516~1518
- Acién P, "Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings", Fertil Steril, 88, pp.32~38 (2007)
- Kitawaki J, "Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas", Hum Reprod, 20, pp.1999~2003 (2005)
- Somigliana E, "Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions", Hum Reprod, 19, pp.1871~1876 (2004)
- Zhang X, "Decreased levels of peritoneal interleukin-1 receptor antagonist in patients with endometriosis and disease-related dysmenorrhea", Fertil Steril, 88, pp.594~599 (2007)